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 Psychological stress has been proposed as a risk factor for the development 
and progression of cancer, including melanoma but evidence is conflicting. 
 Clinical evidence is limited by small sample sizes, potential recall bias 
associated with self-report, and heterogeneous stress definitions.  
What’s new  
 We found a decreased risk of melanoma diagnosis, but an increased mortality 
associated with partner bereavement. 
 While stress might play a role in the progression of melanoma, an alternative 
explanation is that bereaved people no longer have a close person to help 
notice skin changes leading to delayed melanoma detection.   
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Abstract (<=250 words) 
Background: Psychological stress is commonly cited as a risk factor for melanoma 
but clinical evidence is limited.  
Objectives: This study aimed to evaluate the association between partner 
bereavement and: 1) first-time melanoma diagnosis; and 2) mortality in patients with 
melanoma. 
Methods: We conducted two cohort studies using data from the UK Clinical Practice 
Research Datalink (1997-2017) and Danish nationwide registries (1997-2016). Study 
1: We compared risk of first melanoma diagnosis in bereaved with matched non-
bereaved people using stratified Cox regression. Study 2: We estimated HRs for 
death from melanoma in bereaved compared with non-bereaved individuals with 
melanoma using Cox regression. We estimated HRs separately for the UK and for 
Denmark, and then pooled the data to perform a random-effects meta-analysis. 
Results: In Study 1, the pooled adjusted HRs for the association between partner 
bereavement and melanoma diagnosis were 0.88 [95% confidence interval 
(CI),0.84–0.92] across the entire follow-up period. In Study 2, we observed increased 
melanoma-specific mortality in people experiencing partner bereavement across the 
entire follow-up period (HR,1.17; 95% CI,1.06–1.30), with the peak occurring during 
the first year of follow-up (HR,1.31; 95% CI,1.07–1.60). 
Conclusions: We found decreased risk of melanoma diagnosis, but increased 
mortality associated with partner bereavement. These findings may be partly 
explained by delayed detection resulting from the loss of a partner who could notice 
skin changes. Stress may play a role in melanoma progression. Our findings indicate 
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Melanoma is a skin cancer characterised by abnormal growth of melanocytes in an 
existing mole (nevus-associated melanoma) or on normal skin (de novo melanoma). 
Intense sun exposure, pigmentary traits and family history of skin cancer are known 
risk factors of melanoma [1-3]. It is estimated that 197,000 new cases of melanoma 
are diagnosed globally each year, accounting for 1.6% of all incident cancers [4]. In 
the United Kingdom (UK) and Denmark, new melanoma cases account for 5-6% of 
all cancer cases, with approximately 16,000 incident cases diagnosed each year in 
the UK and 2,330 in Denmark [5, 6]. Early melanoma detection and treatment can 
improve survival. In Denmark, 5-year survival of melanoma is 90-94% [5]. In 
England, the 5-year survival rate is 92% in patients with thin tumours (Breslow 
thickness <1.5 mm) but only 42% in those with thick tumours (Breslow thickness 
>4.0 mm) [7].  
Partner bereavement is perceived as one of the most stressful life events [8-10]. 
Psychological stress has been proposed as a risk factor for the development and 
progression of cancer, including melanoma but evidence is conflicting [11-16]. 
Several physiological pathways have been proposed that implicate stress hormones 
in carcinogenesis through effects on immune surveillance [11, 13, 17-19]. However, 
clinical evidence for such association is limited by small sample sizes, potential recall 
bias associated with self-report, and heterogeneous stress definitions [20-25]. Aside 
from stress, recent studies suggest that having a partner can enhance early 
detection of melanoma [26-28]. However, we do not know if partner loss negatively 
affects the incidence and prognosis of melanoma. 
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We used UK and Danish routinely-collected data to conduct population-based cohort 
studies to evaluate associations between partner bereavement and: 1) diagnosis of 
incident melanoma; and 2) melanoma-specific mortality. We also investigated 
whether the associations differed by time since bereavement and whether partner 
loss was expected. 
METHODS 
Settings 
Study data were from UK (January 1997 to July 2017) and Denmark (January 1997 
to December 2016). Both countries provide universal health coverage from publicly 
funded healthcare systems [29, 30].  
In the UK, we used Clinical Practice Research Datalink (CPRD) Gold [31] primary 
care with linked mortality (Office for National Statistics (ONS)), hospital admission 
(Hospital Episode Statistics (HES)), and deprivation data (Index of Multiple 
Deprivation (IMD)) (Supplementary material method 1).  
We used Danish nationwide registries to obtain data on: 1) demographics, civil 
status, and vital status (Civil Registration System [32]); 2) incident melanoma 
(Danish Cancer Registry [33]); 3) causes of death (Danish Registry of Causes of 
Death [34]); 4) diagnoses (Danish National Patient Registry [35]); 5) dispensed 
prescriptions (Danish National Prescription Registry [36]); and 6) education duration 
(Danish Education Registries [37]). Data were linked using the unique personal 
identifier assigned to all Danish residents at birth or immigration. We endeavoured to 
make UK and Danish studies as similar as possible to ensure comparability 
(Supplementary material method 1). 
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Study 1: Melanoma incidence analysis 
We examined the association between partner bereavement and diagnosis of 
incident melanoma using a matched cohort study comparing risk of melanoma 
diagnosis in bereaved individuals with matched non-bereaved individuals. 
In the UK, we identified eligible couples aged 30 and over using a previously 
reported algorithm while [38-42] in Denmark, we used an algorithm provided by 
Statistics Denmark (Supplementary material method 2). Among eligible couples, we 
identified a partner as bereaved (exposed) when their partner died and bereavement 
date was the index date. In the UK, we obtained dates of death from ONS when 
available (59.8%) and from CPRD for persons not linked to ONS (40.2%). In 
Denmark, we used death dates from the Civil Registration System. For each 
bereaved person, we identified a matched comparison cohort who had not previously 
experienced partner bereavement by sampling (with replacement) up to 10 partners 
on age (within 1 year) and sex (both settings), county of residence (Denmark), and 
general practice (UK) on the index date. We excluded all individuals who died on the 
index date as they did not contribute person-time. We also excluded all individuals 
with a diagnosis of melanoma before the index date. We required study participants 
to have ≥1 year of healthcare registration history prior to the index date in the UK, to 
allow adequate time for recording covariates and history of melanoma. 
The outcome was the first-ever recorded diagnosis of melanoma 
(https://datacompass.lshtm.ac.uk/1317/ for UK and Supplementary material method 
3 for Denmark). We followed all cohort members from index date until the first of: a 
melanoma diagnosis, date of last data collection from a members’ practice (UK), 
transfer out of the practice by either member of the couple (UK), emigration of either 
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member of the couple (Denmark), death, or the study end date. If a person in the 
comparison cohort experienced bereavement, he/she was censored one day before 
bereavement and subsequently included in the bereaved cohort (Supplementary 
material figure 1).  
Study 2: Melanoma mortality analysis 
To assess the association between partner bereavement and melanoma-specific 
mortality, we identified a cohort of people diagnosed with melanoma with partners. 
We started follow-up on the date of melanoma diagnosis (Supplementary material 
figure 2).  
Our main outcome was melanoma-specific mortality (Supplementary material 
method 4). We included all-cause mortality as a secondary outcome. In this analysis, 
we started follow-up on the date of melanoma diagnosis and ended at the earliest of: 
the date of last data collection from the patients’ practice (UK), transfer out of 
practice by either member of the couple (UK), emigration of either member of the 
couple (Denmark), death, or study end date. 
Covariates 
As possible confounders, we included comorbidities (original Charlson Comorbidity 
Index (CCI) score) [43], lifestyle covariates (smoking and alcohol consumption) and 
body mass index (BMI), and socioeconomic status (IMD status and education 
duration) (Supplementary material method 5). We hypothesised that the level of 
stress associated with bereavement may depend on whether a partner’s death was 
unexpected. Therefore, we stratified the estimates by the degree to which the 
partner’s death might be considered unexpected based on level of comorbidity (age-
adjusted CCI score for the deceased partner). As an alternative measure, we 
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identified presence of terminal disease among partners recorded before the date of 
death. 
Statistical analysis 
We examined descriptive characteristics for different study cohorts on the follow-up 
start date. We used Cox regression (with time-since cohort entry as the underlying 
timescale) to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for 
the association between partner bereavement and (1) melanoma incidence and (2) 
melanoma-specific mortality. We examined associations for the entire follow-up 
period, and by time since start of follow-up (0–1 year, 0–2 years, 0–3 years, 0–4 
years and 0–5 years) to detect any variation due to time lag in the effect of 
bereavement on outcome for the incidence analysis and to explore the time effect of 
bereavement since melanoma diagnosis for the mortality analysis. For the incidence 
analysis, we stratified regression models by matched set; thus, unadjusted HRs 
accounted for matching factors. In sequential models, we estimated HRs adjusted for 
participants’ CCI level (adjusted model) and then added lifestyle variables and 
deprivation status (UK), and education duration (Denmark) (fully-adjusted model).  
We assessed the assumption of proportional hazards by visual inspection of log-log 
plots (Supplementary material figure 3). Additionally, we examined HRs over time by 
stratifying the follow-up period since bereavement (0–1 year, 1–2 years, 2–3 years, 
3–4 years and 4–5 years, 5+ years) (Supplementary material table 1).  
We also examined variation by age at index date, sex and risk of partner death 
(deceased partner’s age-adjusted CCI score and terminal disease) and performed 
likelihood ratio tests to explore possible effect modification by these characteristics.  
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For the mortality analysis, we included time-varying bereavement as the exposure in 
the unadjusted model. In the adjusted model, we also adjusted for age, sex, and CCI 
score; and in the fully adjusted model we additionally adjusted for lifestyle and 
socioeconomic variables. We also examined the association between bereavement 
and melanoma-specific mortality in categories of cancer stage at diagnosis 
(localised, regional, distant) among patients with this information recorded in the 
Danish Cancer Registry. Finally, we assessed the association between bereavement 
and mortality according to age at melanoma diagnosis and sex and performed 
likelihood ratio tests to analyse effect modification.  
In both analyses, we undertook complete-case analyses in the fully-adjusted models, 
which would be unbiased assuming that missingness was not associated with the 
outcome conditional on the other variables. As lifestyle data (used in UK analyses 
only) are unlikely to be missing at random and we lacked data on probable predictors 
of missingness, imputation techniques were not appropriate for correcting potential 
biases [44]. For the incidence analysis, we further investigated patterns of missing 
data using conditional logistic regression. We conducted several sensitivity analyses 
to test the robustness of the results in both incidence and mortality analyses 
(Supplementary material table 2). All study analyses were pre-planned unless 
otherwise stated. 
We conducted all analyses separately for the UK (using Stata/MP 15.1) and 
Denmark (using SAS 9.4). We combined the main results (from the adjusted models) 
in Stata using DerSimonian and Lairds’ random-effects model [45].  
RESULTS 
Study 1: Melanoma incidence analysis 
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The study included 170,002 bereaved and 1,599,260 matched non-bereaved 
individuals in the UK; and 345,915 bereaved and 3,319,788 matched non-bereaved 
individuals in Denmark (Figure 1). Median age was 74 years in the UK and 71 years 
in Denmark. Approximately two-third of both cohorts were women (Table 1). 
Bereaved people were more likely to have higher CCI scores, to be more deprived, 
to have a shorter education, and to have slightly longer median follow-up than 
people in the comparison cohort.  
The pooled HR (adjusted for study participants’ CCI scores) comparing melanoma 
diagnosis rates in bereaved to non-bereaved individuals was 0.88 (95% CI, 0.84–
0.92) (Figure 2). We did not find evidence of lower HRs for melanoma within 0–1 
year (0.97; 95% CI,0.86–1.09) and 0–2 years (0.94; 95% CI,0.83–1.05). However, 
we found evidence of a lower melanoma rate following partner bereavement within 
0–3 years (0.89; 95% CI,0.83–0.96), 0–4 years (0.90; 95% CI,0.85–0.96) and 0–5 
years (0.88; 95% CI,0.83–0.93) of follow-up. Estimates were similar in the fully 
adjusted models (Supplementary material table 3). 
We found evidence of effect modification by age in the UK but not in Denmark 
(Supplementary material table 4). We observed no substantial variation by sex or 
whether partner’s death was forseen in both countries.  
In the UK, missing lifestyle data was dependent on incident melanoma, conditional 
on bereavement status and other covariates (Supplementary material table 5). 
However, HRs for the whole cohort and the complete-case cohort were similar in the 
unadjusted and adjusted models in both countries (Supplementary material table 6). 
The results of sensitivity analyses were broadly similar to those of the main analyses 
(Supplementary material tables 7–12).  
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Study 2: Melanoma mortality analysis 
We followed 3597 patients with melanoma in the UK and 24,911 people with 
melanoma in Denmark (Figure 1). Median follow-up time was 3.5 years in the UK 
and 5.0 years in Denmark (Table 2). More people who were under age 50 and had  
fewer comorbidities were included in Denmark compared with the UK. In Denmark, 
most individuals had localised cancer at diagnosis (74.6%). Among 2162 individuals 
who experienced bereavement on/prior to melanoma diagnosis, 1,485 (68.7%) had 
localised melanoma, 135 (6.2%) had regional melanoma, 24 (1.1%) individuals had 
distant cancer at diagnosis. 
After adjusting for age, sex and study participants’ CCI score, we observed an 
increased melanoma-specific mortality in those with partner bereavement (pooled 
HR,1.17; 95% CI,1.06–1.30) compared with those without (Figure 3). The analysis 
by time-since melanoma diagnosis showed that the increased HR for melanoma-
specific mortality in the bereaved compared with the non bereaved peaked within 0–
1 year (1.31; 95% CI,1.07–1.60) of follow-up and remained stable during 0–2 years 
(1.19; 95% CI,1.02–1.38), 0–3 years (1.21; 95% CI,1.06–1.38), 0–4 years (1.21; 
95% CI,1.07–1.36), and 0–5 years (1.20; 95% CI,1.07–1.35) of follow-up. Similar 
HRs were observed in the fully adjusted models (Supplementary material table 13). 
HRs generated by unadjusted and adjusted models for the whole cohort and the 
complete-case cohort were similar in both countries (Supplementary material table 
14). Additionally, we observed approximately 20-30% increased hazard of all-cause 
mortality associated with partner bereavement during the entire follow-up period in 
both countries (Supplementary material table 15).  
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Wide CIs were observed for all subgroups due to small sample size (Supplementary 
material table 16). In Denmark, we did not find evidence of effect modification by 
cancer stage (Supplementary material table 17). Results of all other sensitivity 




This study showed that partner bereavement was associated with a 12% decreased 
risk of being diagnosed with incident melanoma in two large population-based 
studies. We observed an increase in melanoma-specific mortality associated with 
partner bereavement, which peaked during the first year following melanoma 
diagnosis. 
Comparison with other studies 
Several studies have examined the role of other stressors in melanoma incidence, 
but no studies have focused on partner bereavement and melanoma [12, 20, 21]. A 
meta-analysis showed no association between risk of skin cancers, including 
melanoma, and stress-related psychosocial factors such as stressful life events, 
severe chronic stress and daily stress [12]. However, the review did not assess 
studies focusing on melanoma only. In contrast, a case-control study assessing self-
reported loss of a relative or friend in the past year reported an increased risk of 
melanoma in bereaved individuals [20]. Our observed lower rate of melanoma 
diagnosis in bereaved people may reflect delayed melanoma detection after partner 
loss. Supporting this theory, a recent randomised controlled trial reported that 
providing structured skin self-examination education intervention to patients with 
prior melanoma and their partners resulted in identification of more melanomas 
compared with customary care, including identification of more in situ melanomas 
[26]. Another study reported that people married at melanoma diagnosis, were 2 to 3 
times more likely to have a thinner tumour than non-married individuals [28]. A 
cohort study based on data from the United States National Cancer Institute’s 
Surveillance, Epidemiology, and End Results database also showed that widowed 
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people were less likely to undergo sentinel lymph node biopsy and more likely to 
present with a higher stage of melanoma compared with married people [27]. These 
studies suggest the partner loss could decrease early diagnosis of melanoma, which 
is consistent with our findings. Social isolation, residual socioeconomic confounding, 
reduced self-care and reduced likelihood of seeking medical attention following 
bereavement may also have contributed to the lower incidence of diagnosed 
melanoma we observed. Our study highlights the importance of encouraging family 
members or caregivers to perform skin examinations for bereaved persons. 
It has been suggested that stress hormones can accelerate growth and migration of 
tumour cells, worsening melanoma prognosis, as immunologic surveillance is 
important in melanoma outcomes [13, 17, 18]. Consistent with our findings, two small 
studies reported that a range of positive psychosocial factors (including marriage) 
predicted longer survival following melanoma [22, 25], while another found no 
association with time to relapse among 155 patients with melanoma or breast cancer 
[23, 24]. A meta-analysis showed no significant effects of stress-related psychosocial 
factors on skin cancer survival (melanoma and non-melanoma) [12]. All of these 
prior studies suffered from limitations including inadequate power, inclusion of a wide 
range of psychological constructs, and lack of control for other risk factors [22-25, 
46], but the results were similar to our study. A previous study [38] reported a short-
term increased risk of cardiovascular events within 90 days after partner 
bereavement, suggesting that cardiovascular events may partly explain our 
observation of increased all-cause mortality up to 5 years following bereavement, 




Apart from stress, delayed detection of recurrence or a secondary melanoma due to 
lack of an available partner to notice skin changes might also account for our 
findings. Unfortunately, our stage-specific analyses in Denmark were associated with 
large statistical imprecision precluding firm conclusions. Previous studies have 
shown that those without a partner experienced higher death rates [47], shorter 
survival [48-52], and advanced stage of melanoma at time of diagnosis [50, 53, 54]. 
However, most studies have focused on women only [47, 48] or lacked adjustment 
for lifestyle factors [51, 52] or socioeconomic status [49, 50].  
Strengths and weaknesses 
Combining population-based data from two countries (UK and Denmark), provides 
credibility to our findings by demonstrating replicability, attaining a greater sample 
size, exploring various sources of bias (e.g., confounding by lifestyle factors), and 
the use of validated outcomes. Validation studies have shown high positive 
predictive values (≥83%) of identifying melanoma cases based on data both in the 
CPRD and the Danish Cancer Registry [55, 56]. 
To control for potential confounding, we adjusted our analyses for socioeconomic 
status and lifestyle variables. However, we did not have information on some risk 
factors of melanoma including sun exposure, pigmentary traits and family history of 
skin cancer. Residual confounding is a possibility. We matched our cohort with 
replacement in the main analysis in both settings, which might have led to narrower 
confidence intervals. Excluding people with missing lifestyle information in the UK 
had minimal effects on estimates, implying that this missing data was unlikely to 
have affected our interpretation of results. Misclassification of partnership also could 
have occurred including changes in partner status over time. Particularly in the UK 
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where direct data on partnership status were not available may have led to non-
differential misclassification and underestimation of any association. However, we 
used relatively strict criteria (e.g., age difference of members of the couples) to 
identify partners in the UK, to minimise such misclassification [38-41]. Importantly, 
longitudinal data on partnership were available in the Danish study, and findings 
were broadly similar to those of the UK study. 
CONCLUSIONS 
We observed a lower risk of a melanoma diagnosis following partner bereavement. 
This finding might be explained by delayed detection in the absence of partner help 
with skin examinations among the bereaved. This mechanism could also explain the 
increase in melanoma mortality associated with partner bereavement, although 
stress might promote melanoma progression. Our findings highlight the need for 
raising public awareness of the association to perform self-skin examination, as well 
as encouraging clinicians to have a lower threshold for undertaking skin 
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Table 1. Study 1: Characteristics of the bereaved and matched comparison cohorts 
used in the melanoma incidence analysis 









Total 170,002 (9.6) 1,599,260 (90.4) 345,915 (9.4) 3,319,788 (90.6) 
Age at index date, 
years 
    
Range 31.9-101.4 31.4-100.4 16.5-100.0 16.1-99.9 
Median (IQR) 74.5 (66.8-80.8) 73.8 (66.3-79.8) 71.3 (62.4-78.8) 70.8 (62.0-78.0) 
Groups     
<50 3081 (1.8) 30,096 (1.9) 23,956 (6.9) 238,640 (7.2) 
50–59  15,843 (9.3) 158,537 (9.9) 45,143 (13.1) 449,727 (13.5) 
60–69  39,239 (23.1) 391,003 (24.5) 89,214 (25.8) 887,777 (26.7) 
70–79  64,000 (37.7) 630,668 (39.4) 114,708 (33.2) 1,123,948 (33.9) 
≥80 47,839 (28.1) 388,956 (24.3) 72,894 (21.1) 619,696 (18.7) 
Sex     
   Women 111,427 (65.5) 1,048,995 (65.6) 231,022 (66.8) 2,214,531 (66.7) 
Comorbidity burdenb     
Low  78,347 (46.1) 773,297 (48.4) 249,026 (72.0) 2,458,135 (74.0) 
Intermediate  62,126 (36.5) 571,089 (35.7) 81,430 (23.5) 728,846 (22.0) 
High 29,529 (17.4) 254,874 (15.9) 15,459 (4.5) 132,807 (4.0) 
Smoking  statusc     
Non-smoker 61,330 (36.1) 624,987 (39.1) NA NA 
Ex-smoker 69,069 (40.6) 666,389 (41.7) NA NA 
Current smoker 36,862 (21.7) 286,561 (17.9) NA NA 
Missing 2741 (1.6) 21,323 (1.3) NA NA 
Alcohol consumptionc 
Non-drinker 19,913 (11.7) 169,930 (10.6) NA NA 
Ex-drinker 22,128 (13.0) 185,976 (11.6) NA NA 
Current drinker 114,823 (67.5) 1,134,558 (70.9) NA NA 
Missing 13,138 (7.7) 108,796 (6.8) NA NA 
Body Mass Indexc     
<18.5 kg/m2 4216 (2.5) 28,321 (1.8) NA NA 
18.5-24.9 kg/m2 57,830 (34.0) 544,495 (34.1) NA NA 
25-29.9 kg/m2 58,967 (34.7) 590,334 (36.9) NA NA 
≥30 kg/m2 35,856 (21.1) 333,589 (20.9) NA NA 
Missing 13,133 (7.7) 102,521 (6.4) NA NA 
Index of multiple deprivationc 
1 (least deprived) 39,713 (23.4) 400,092 (25.0) NA NA 
2 35,361 (20.8) 345,884 (21.6) NA NA 
3 36,653 (21.6) 344,956 (21.6) NA NA 
4 33,049 (19.4) 292,864 (18.3) NA NA 
5 (most deprived) 25,226 (14.8) 215,464 (13.5) NA NA 
26 
 
Education durationd     
Short (7-10 years) NA NA 157,611 (45.6) 1,370,756 (41.3) 
Medium (11-12 
years) 
NA NA 103,144 (29.8) 1,058,069 (31.9) 
Long (≥13 years) NA NA 40,506 (11.7) 526,196 (15.9) 
Missing NA NA 44,654 (12.9) 364,767 (11.0) 
Follow-up (years)     
Total 905,281 8,137,952 2,552,711 22,027,622 
   Median (IQR) 4.3 (1.8-8.1) 4.1 (1.8-7.5) 6.6 (3.0-11.2) 5.6 (2.5-10.0) 
Abbreviations: IQR, interquartile range, NA, not applicable 
aIn the UK comparison cohort, 18.7% (15.1% of unique subjects) experienced bereavement after the 
end of follow-up. In the Danish comparison cohort, 22.7% (17.0% of unique subjects) experienced 
bereavement after the end of follow-up. 
bComorbidity burden was measured using the Charlson Comorbidity Index. Comorbidity burden was 
determined on the index date based on the Charlson Comorbidity Index score, categorised as low (0 
point), intermediate (1-2 points), and high (≥3 points). 
cInformation on smoking status, alcohol consumption, body mass index and index of multiple 
deprivation was not available in Denmark. 




Table 2. Study 2: Characteristics of patients with melanoma among couples in the 
mortality analysis 
 UK, No. (%) Denmark, No. (%) 
Total 3597 24,911 
Age, years   
Range 32.8-99.0 18.3-99.5 
Median (IQR) 67.2 (58.2-75.5) 58.7 (45.3-69.8) 
Groups   
<50 283 (7.9) 8,276 (33.2) 
50–59  782 (21.7) 4,888 (19.6) 
60–69  1092 (30.4) 5,633 (22.6) 
70–79  958 (26.6) 4,051 (16.3) 
80+  482 (13.4) 2,063 (8.3) 
Sex   
   Women 1606 (44.7) 13,035 (52.3) 
   Men 1991 (55.4) 11,876 (47.7) 
Comorbidity burdena   
Low  1858 (51.7) 20,254 (81.3) 
Intermediate  1117 (31.1) 3,847 (15.4) 
High  622 (17.3) 810 (3.3) 
Smoking statusb   
Non-smoker 1415 (39.3) NA 
Ex-smoker 1559 (43.3) NA 
Current smoker 595 (16.5) NA 
Missing 28 (0.8) NA 
Alcohol consumptionb   
Non-drinker 236 (6.6) NA 
Ex-drinker 266 (7.4) NA 
Current drinker 2832 (78.7) NA 
Missing 263 (7.3) NA 
Body Mass Indexb   
<18.5 kg/m2 43 (1.2) NA 
18.5-24.9 kg/m2 1172 (32.6) NA 
25-29.9 kg/m2 1405 (39.1) NA 
≥30 kg/m2 754 (21.0) NA 
Missing 223 (6.2) NA 
Index of multiple deprivationb   
1 (least deprived) 1099 (30.6) NA 
2 1019 (28.3) NA 
3 788 (21.9) NA 
4 522 (14.5) NA 
5 (most deprived) 169 (4.7) NA 
Education durationc   
Short (7-10 years) NA 5,909 (23.7) 
Medium (11-12 years) NA 10,410 (41.8) 
Long (≥13 years) NA 7,563 (30.4) 
Missing NA 1,029 (4.1) 
Melanoma stage at diagnosisc   
Localised NA 18,575 (74.6) 
Regional NA 1,500 (6.0) 
Distant NA 254 (1.0) 
Unknown NA 4,582 (18.4) 
28 
 
Follow-up (years)   
Total 17,625 154,189 
   Median (IQR) 3.5 (1.4-6.8) 5.0 (2.2-9.3) 
Abbreviations: IQR, interquartile range; NA, not applicable 
aComorbidity burden was measured using the Charlson Comorbidity Index. Comorbidity burden was 
determined on the index date using the Charlson Comorbidity Index score, categorised as low (0 
point), intermediate (1-2 points), and high (≥3 points).  
bInformation on smoking status, alcohol consumption, body mass index and index of multiple 
deprivation was not available in Denmark. 







Figure 1. Flowcharts for inclusion in the UK and Denmark cohorts. Figure 1a: the 
incidence analysis in the UK; Figure 1b: the incidence analysis in Denmark; 
Figure1c: the mortality analysis in the UK; Figure 1d: the mortality analysis in 
Denmark 
Figure 2. Pooled adjusted hazard ratios for the association between partner 
bereavement and diagnosis of incident melanoma in the UK and Denmark. Hazard 
ratios were adjusted for Charlson Comorbidity Index scores. 
Figure 3. Pooled adjusted hazard ratios for the association between partner 
bereavement and melanoma-specific mortality among patients with melanoma in the 
UK and Denmark. Hazard ratios were adjusted for age, sex, and Charlson 
Comorbidity Index scores. 
 
